Patients with Crohn’s disease can be effectively placed in clinical remission with the combination of infliximab and immunosuppressants. However, long-term use poses some dangers. Scientists from Liege have therefore investigated how discontinuation of one of the components affects remission.
This content is machine-translated. Please contact us if you need professional translation services.
- GASTROENTEROLOGIE PRAXIS